

## EQA round: CSFB1/24 - Cerebrospinal Fluid Analysis

Deadline: 22.3.2024

Setup: groups - R (manufacturer of kit); minimal size of the groups n = 5

RoM = robust average

SD = standard deviation

CV = coefficient of variation

N<sub>tot</sub> = total number of the resultsN<sub>out</sub> = number of the results removed before calculation

AV = assigned value

CVP = consensus of all participants

U<sub>AV</sub> = expanded uncertainty of the assigned value (k = 2)D<sub>max</sub> = acceptable difference

LL = lower limit

UL = upper limit

N<sub>eva</sub> = number of the results assessedN<sub>suc</sub> = number of successful resultsS<sub>rel</sub> = relative success

Test Sample Group	[unit]	RoM	SD	CV [%]	N <sub>tot</sub>	N <sub>out</sub>	Comparability					N <sub>eva</sub>	N <sub>suc</sub>	S <sub>rel</sub> [%]	
							AV	U <sub>AV</sub>	D <sub>max</sub>	LL	UL				
<b>(333) Albumin</b>	[mg/L]				75							75	72	96	
<b>Sample A</b>		240	20	8,2	75		CVP	240	5,6	23%	184	296	75	72	96
(1) Abbott		255	3	1,2	7	0							7		
(58) Beckman Coulter (AU)		243	5,2	2,1	9	0							9		
(60) Roche		238	8,9	3,7	23	0							23		
(149) Siemens (Dade, BN, Dimension)		259	15	5,8	11	0							11		
(162) Siemens (Atellica)		210	30	14	12	0							12		
(179) Siemens		233	8,9	3,8	6	0							6		
Other					7	0							7		
								3x 12, 3x 91, 1x 152							
<b>Sample B</b>		346	27	7,7	75		CVP	346	7,5	23%	266	426	75	74	99
(1) Abbott		365	5,9	1,6	7	0							7		
(58) Beckman Coulter (AU)		350	7,5	2,1	9	0							9		
(60) Roche		342	11	3,2	23	0							23		
(149) Siemens (Dade, BN, Dimension)		371	21	5,7	11	0							11		
(162) Siemens (Atellica)		308	52	17	12	0							12		
(179) Siemens		341	24	7,2	6	0							6		
Other					7	0							7		
								3x 12, 3x 91, 1x 152							
<b>(330) Total protein</b>	[mg/L]				98							98	96	98	
<b>Sample A</b>		405	24	5,8	98		CVP	405	5,9	27%	295	515	98	97	99
(1) Abbott		404	24	6	11	0							11		
(58) Beckman Coulter (AU)		417	10	2,5	14	0							14		
(60) Roche		397	18	4,5	41	0							41		
(162) Siemens (Atellica)		425	21	4,9	16	0							16		
Other					16	0							16		
								2x 46, 1x 75, 3x 77, 1x 85, 1x 115, 1x 158, 1x 166, 1x 178, 4x 179, 1x 998							
<b>Sample B</b>		904	50	5,5	98		CVP	904	12	27%	659	1150	98	96	98
(1) Abbott		916	54	5,9	11	0							11		
(58) Beckman Coulter (AU)		925	15	1,7	14	0							14		
(60) Roche		928	23	2,5	41	0							41		
(162) Siemens (Atellica)		865	27	3,1	16	0							16		
Other					16	0							16		
								2x 46, 1x 75, 3x 77, 1x 85, 1x 115, 1x 158, 1x 166, 1x 178, 4x 179, 1x 998							
<b>(331) Glucose</b>	[mmol/L]				98							98	98	100	
<b>Sample A</b>		3,48	0,11	3	98		CVP	3,48	0,026	18%	2,85	4,11	98	98	100
(1) Abbott		3,46	0,089	2,6	9	0							9		
(46) Erba Lachema		3,57	0,19	5,4	6	0							6		
(58) Beckman Coulter (AU)		3,46	0,12	3,5	16	0							16		
(60) Roche		3,46	0,074	2,1	40	0							40		
(162) Siemens (Atellica)		3,51	0,095	2,7	17	0							17		
Other					10	0							10		
								1x 75, 2x 158, 1x 178, 4x 179, 1x 187, 1x 188							
<b>Sample B</b>		1,84	0,064	3,5	98		CVP	1,84	0,016	18%	1,5	2,18	98	98	100
(1) Abbott		1,8	0,059	3,3	9	0							9		
(46) Erba Lachema		1,87	0,059	3,2	6	0							6		
(58) Beckman Coulter (AU)		1,82	0,085	4,7	16	0							16		
(60) Roche		1,83	0,044	2,4	40	0							40		
(162) Siemens (Atellica)		1,88	0,071	3,8	17	0							17		
Other					10	0							10		
								1x 75, 2x 158, 1x 178, 4x 179, 1x 187, 1x 188							
<b>(335) IgA</b>	[mg/L]				21							21	21	100	
<b>Sample A</b>		10,4	0,58	5,6	21		CVP	10,4	0,31	32%	7,07	13,8	21	21	100
(149) Siemens (Dade, BN, Dimension)		10,2	0,54	5,3	10	0							10		
Other					11	0							11		
								3x 12, 3x 91, 3x 162, 2x 179							
<b>Sample B</b>		18,3	1,6	9	21		CVP	18,3	0,88	32%	12,4	24,2	21	21	100
(149) Siemens (Dade, BN, Dimension)		17,6	1,2	7	10	0							10		
Other					11	0							11		
								3x 12, 3x 91, 3x 162, 2x 179							
<b>(334) IgG</b>	[mg/L]				42							42	42	100	
<b>Sample A</b>		56,7	2,8	5	42		CVP	56,7	1,1	24%	43	70,4	42	42	100
(60) Roche		55,4	2,1	3,7	14	0							14		
(91) Binding Site		57,7	1,4	2,5	5	0							5		

